Defining a Noncarcinogenic Dose of Recombinant Human Parathyroid Hormone 1–84 in a 2-Year Study in Fischer 344 Rats

Toxicologic Pathology

Volumn 34, Issue 7, 2006, Pages 929-940

  Jolette, Jacquelin ^a   Wilker, Clynn E ^b   Smith, Susan Y ^a   Doyle, Nancy ^a   Hardisty, Jerry F ^c   Metcalfe, Anna J ^d   Marriott, Thomas B ^b   Fox, John ^b   Wells, David S ^b  

^a CHARLES RIVER LABORATORIES   (United States)

^b NPS Pharmaceutical Inc   (United States)

^c EXPERIMENTAL PATHOLOGY LABORATORIES INC   (United States)

^d Cantox Health Sciences International   (Canada)

Author keywords

bone; carcinogenicity; F344 rat; neoplasm; osteoporosis treatment; osteosarcoma; Parathyroid hormone

Indexed keywords

PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE[1-34];

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CANCER; BONE DEFECT; BONE DENSITY; BONE MINERAL; BONE TISSUE; CARBOXY TERMINAL SEQUENCE; CELL HYPERPLASIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; FEMUR; FIBROSARCOMA; FISCHER 344 RAT; HISTOPATHOLOGY; INCIDENCE; LOW DRUG DOSE; MALE; NONHUMAN; OSTEOBLAST; OSTEOMA; OSTEOSARCOMA; OSTEOSCLEROSIS; PRIORITY JOURNAL; RADIOGRAPHY; RAT; SOFT TISSUE; VERTEBRA;

ANIMALS; AREA UNDER CURVE; BONE DENSITY; BONE NEOPLASMS; DENSITOMETRY; FEMALE; FIBROSARCOMA; HUMANS; HYPERPLASIA; INJECTIONS, SUBCUTANEOUS; MALE; OSTEOBLASTOMA; OSTEOBLASTS; OSTEOSARCOMA; OSTEOSCLEROSIS; PARATHYROID HORMONE; RATS; RATS, INBRED F344; RECOMBINANT PROTEINS; SEX FACTORS;

EID: 33845769891     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230601072301     Document Type: Article

References (26)

1. Bringhurst FR PTH receptors and apoptosis in osteocytes J Musculoskelet Neuronal Interact 2002 2 245 51
2. Dempster DW Cosman F Parisien M Shen V Lindsay R Anabolic actions of parathyroid hormone on bone Endocr Rev 1993 14 690 709
3. Divieti P Inomata N Chapin K Singh R Juppner H Bringhurst FR Receptors for the carboxyl-terminal region of pth(1–84) are highly expressed in osteocytic cells Endocrinology 2001 142 916 25
4. Divieti P John MR Juppner H Bringhurst FR Human PTH-(7–84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor Endocrinology 2002 143 171 6
5. Eli Lilly and Company Forteo prescribing information 2004 Indianapolis, Indianapolis, IN
6. Fox J Developments in parathyroid hormone and related peptides as bone-formation agents Curr Opin Pharmacol 2002 2 338 44
7. Inomata N Akiyama M Kubota N Juppner H Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1–84) Endocrinology 1995 136 4732 40
8. Jilka RL Weinstein RS Bellido T Roberson P Parfitt AM Manolagas SC Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone J Clin Invest 1999 104 439 46
9. Langub MC Monier-Faugere MC Wang G Williams JP Koszewski NJ Malluche HH Administration of PTH-(7–84) antagonizes the effects of PTH-(1–84) on bone in rats with moderate renal failure Endocrinology 2003 144 1135 8
10. Leininger JR Riley MGI Boorman GA Eustis SL Elwell MR Montgomery CA Jr MacKenzie WF Bone, joints and synovia Pathology of the Fischer rat. Reference and Atlas 1990 San Diego, CA Academic Press
11. Lin KK Rahman MA Overall false positive rates in tests for linear trend in tumor incidence in animal carcinogenicity studies of new drugs J Biopharm Stat 1998 8 1 15 17 22
12. Murray TM Rao LG Divieti P Bringhurst FR Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands Endocr Rev 2005 26 78 113
13. Murray TM Rao LG Muzaffar SA Ly H Human parathyroid hormone carboxyterminal peptide (53–84) stimulates alkaline phosphatase activity in dexamethasone-treated rat osteosarcoma cells in vitro Endocrinology 1989 124 1097 9
14. Neer RM Arnaud CD Zanchetta JR Prince R Gaich GA Reginster JY Hodsman AB Eriksen EF Ish-Shalom S Genant HK Wang O Mitlak BH Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 2001 344 1434 41
15. Nguyen-Yamamoto L Rousseau L Brossard JH Lepage R D’Amour P Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor Endocrinology 2001 142 1386 92
16. Nguyen-Yamamoto L Rousseau L Brossard JH Lepage R Gao P Cantor T D’Amour P Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays Eur J Endocrinol 2002 147 123 31
17. Peto R Pike MC Day NE Gray RG Lee PN Parish S Peto J Richards S Wahrendorf J Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments IARC Monogr Eval Carcinog Risk Chem Hum Suppl 1980 311 426
18. Schwamm HA Millward CL Histologic Dfferential Diagnosis of Skeletal Lesions 1995 New York Igaku-Shoin
19. Slatopolsky E Finch J Clay P Martin D Sicard G Singer G Gao P Cantor T Dusso A A novel mechanism for skeletal resistance in uremia Kidney Int 2000 58 753 61
20. Stanton MF Turosov VS Mohr U Tumor of the bone Pathology of Tumours in Laboratory Animals. Volume 2: Tumours of the Mouse 1979 Lyon, France International Agency of Research on Cancer
21. Struman I Bentzien F Lee H Mainfroid V D’Angelo G Goffin V Weiner RI Martial JA Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis Proc Natl Acad Sci USA 1999 96 1246 51
22. Thurman JD Bucci TJ Mohr U Dungworth DL Capen CC Hyperostosis in the F344 rat Pathobiology of the Aging Rat 1994 Washington, DC ILSI Press
23. U.S. Food and Drug Administration Development of parathyroid hormone for the treatment and prevention of osteoporosis 2000 Rockville, MD Center for Drug Evaluation and Research
24. Vahle JL Long GG Sandusky G Westmore M Ma YL Sato M Bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose Toxicol Pathol 2004 32 426 38
25. Vahle JL Sato M Long GG Young JK Francis PC Engelhardt JA Westmore MS Linda Y Nold JB Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety Toxicol Pathol 2002 30 312 21
26. Zwicker GM Eyster RC Proliferative bone lesions in rats fed a diet containing glucocorticoid for up to two years Toxicol Pathol 1996 24 246 50